Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.895 -0.035 (-0.35%)
Streaming Delayed Price Updated: 11:07 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About Arvinas
 
Via Benzinga
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
Via Stocktwits
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
Forecasting The Future: 7 Analyst Projections For Arvinas
 
Via Benzinga
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
From Arvinas Inc.
Via GlobeNewswire
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market. 
Via Chartmill
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
From Arvinas Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
From Arvinas Inc.
Via GlobeNewswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
From Pomerantz LLP
Via GlobeNewswire
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.